Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K Zahn

Showing results (431-440 of 435) with videos related to

Pageof 44
Sort By:
You have reached the last page of results.This site can display upto 435 results.
Molecular Cancer Therapeutics|July 22, 2017
The IGF1R/INSR Inhibitor BI 885578 Selectively Inhibits Growth of IGF2-Overexpressing Colorectal Cancer Tumors and Potentiates the Efficacy of Anti-VEGF TherapyMichael P Sanderson, Marco H Hofmann, Pilar Garin-Chesa, et al.
Molecular Autism|June 14, 2023
Shank2 identifies a subset of glycinergic neurons involved in altered nociception in an autism modelFlorian Olde Heuvel, Najwa Ouali Alami, Oumayma Aousji, et al.
Molecular Cancer Therapeutics|August 7, 2016
Pharmacological Profile of BI 847325, an Orally Bioavailable, ATP-Competitive Inhibitor of MEK and Aurora KinasesPatrizia Sini, Ulrich Gürtler, Stephan K Zahn, et al.
Chemmedchem|December 4, 2020
Getting a Grip on the Undrugged: Targeting β-Catenin with Fragment-Based MethodsDirk Kessler, Moriz Mayer, Stephan K Zahn, et al.
Journal of Medicinal Chemistry|August 1, 2019
Intracellular Trapping of the Selective Phosphoglycerate Dehydrogenase (PHGDH) Inhibitor <b>BI-4924</b> Disrupts Serine BiosynthesisHarald Weinstabl, Matthias Treu, Joerg Rinnenthal, et al.
Pageof 44

Showing results (431-440 of 435) with videos related to

Sort By:
Pageof 44
You have reached the last page of results.This site can display upto 435 results.
Molecular Cancer Therapeutics|July 22, 2017
The IGF1R/INSR Inhibitor BI 885578 Selectively Inhibits Growth of IGF2-Overexpressing Colorectal Cancer Tumors and Potentiates the Efficacy of Anti-VEGF TherapyMichael P Sanderson, Marco H Hofmann, Pilar Garin-Chesa, et al.
Molecular Autism|June 14, 2023
Shank2 identifies a subset of glycinergic neurons involved in altered nociception in an autism modelFlorian Olde Heuvel, Najwa Ouali Alami, Oumayma Aousji, et al.
Molecular Cancer Therapeutics|August 7, 2016
Pharmacological Profile of BI 847325, an Orally Bioavailable, ATP-Competitive Inhibitor of MEK and Aurora KinasesPatrizia Sini, Ulrich Gürtler, Stephan K Zahn, et al.
Chemmedchem|December 4, 2020
Getting a Grip on the Undrugged: Targeting β-Catenin with Fragment-Based MethodsDirk Kessler, Moriz Mayer, Stephan K Zahn, et al.
Journal of Medicinal Chemistry|August 1, 2019
Intracellular Trapping of the Selective Phosphoglycerate Dehydrogenase (PHGDH) Inhibitor <b>BI-4924</b> Disrupts Serine BiosynthesisHarald Weinstabl, Matthias Treu, Joerg Rinnenthal, et al.
Pageof 44